Viewing data from:

DAYSEE

ANDA

ETHINYL ESTRADIOL; LEVONORGESTREL | A091467 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: QUARTETTE(TE code: AB)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
TEVA WOMEN'S HEALTH, INC. v. LUPIN, LTD. et al 3:2010cv00603 1 patentANDA 091467ethinyl estradiol and levonorgestrel	D.N.J.	2010-02-03	Terminated 2012-06-29	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.1350

per ea

Lowest NADAC/Unit

$0.1350

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68180084613DAYSEE 0.15-0.03-0.01 MG TAB	$0.1350	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Daysee (2024)

Total Spending

$97K

Total Claims

1,838

Beneficiaries

702

Avg Cost/Unit

$0.58

Spending Trend

$180K(2019)→$146K(2020)→$87K(2021)→$106K(2022)→$137K(2023)→$97K(2024)

YoY Change:-28.1%

5yr CAGR:-20.0%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Products (1)

#001 — 0.03MG,0.01MG;0.15MG,N/A

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 10, 2013

No patent or exclusivity listings for this strength.